2020 American Transplant Congress
Pneumocystis Pneumonia Occurrence and Prophylaxis Duration in Kidney Transplant Recipients According to Perioperative Treatment with Rituximab
Department of Surgery, Division of Kidney and Pancreas Transplant, AMC, Seoul, Korea, Republic of
*Purpose: Pneumocystis pneumonia (PCP) is a life-threatening fungal infection that can occur in kidney transplantation (KT) recipients. A growing number of KT recipients are receiving…2020 American Transplant Congress
Three-Month Results of a Phase 2 Trial Evaluating Clazakizumab in Late Antibody-Mediated Rejection – Early Impact of Interleukin-6 Blockade on Donor-Specific Antibody Levels, Rejection Morphology and Gene Expression
*Purpose: Targeting Interleukin-6 (IL-6) is a promising strategy to counteract antibody-mediated rejection (ABMR). This phase 2 trial (NCT03444103) was designed to evaluate the safety and…2020 American Transplant Congress
New Strategy to Maximize Nanomedicine Delivery During Ex Vivo Organ Perfusion
*Purpose: Organ transplant is a highly successful therapy for patients facing end stage organ failure. However, there is a severe lack of transplantable organs which…2020 American Transplant Congress
Early Impact of Interleukin-6 Blockade on the Distribution of Peripheral Blood Immune Cell Subpopulations – 3-Month Results of a Phase 2 Trial Evaluating Clazakizumab in Late Antibody-Mediated Rejection
*Purpose: Interleukin-6 (IL-6) is considered to play a critical role within the multifacted pathophysiological process of antibody-mediated rejection (ABMR), including modulation of regulatory T cells…2019 American Transplant Congress
The Effects of Anti-BAFF Monoclonal Antibody in the HLA-A2 Sensitized Mouse Model
*Purpose: B-cell activating factor (BAFF) is a cytokine that plays a role in the survival, proliferation and differentiation of B-cells. The aim of this study…2019 American Transplant Congress
Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection in Solid Organ Transplant Recipients at an Academic Medical Center
Center for Transplantation, University of California, San Diego Health System, La Jolla, CA
*Purpose: In the United States, the incidence of Clostridium difficile infection (CDI) has increased remarkably and remains a significant burden in the solid organ transplant…2019 American Transplant Congress
Intravenous Immunoglobulin Significantly Reduces Bioavailability of Concomitantly Administered Anti-C5 Monoclonal Antibodies
*Purpose: Awareness of drug-drug interactions is critical in management of organ transplant recipients. However, there is little understanding of the possibility of biologic agents interfering…2019 American Transplant Congress
Characterization of HLA Antibodies by C3d Assay and IgG Subclasses in Sensitized Kidney Transplant Patients
Instituto Nacional de Ciencias Medicas y Nutricion SZ, Mexico City, Mexico
*Purpose: To determine the detection rate of IgG subclasses (IgGsc) and C3d-binding HLA-antibodies (abs) in a cohort of highly sensitized kidney transplant patients.*Methods: We evaluated,…2019 American Transplant Congress
Rituximab Protects against Development of Atherosclerotic Cardiovascular Disease after Kidney Transplantation, a Propensity Matched Analysis
Severance hospital, Seoul, Korea, Republic of
*Purpose: Recent studies have implicated B cells in atherosclerosis and have verified the atheroprotective effect of rituximab. We sought to explore the effects of rituximab…2017 American Transplant Congress
Extended Experience with Tocilizumab (Anti-IL6R) for Difficult to Desensitize (Des) Patients Awaiting HLA Incompatible Kidney Transplant.
Kidney Transplant, Cedars-Sinai Medical Center, LA, CA
INTRODUCTION: ~30% of HS patients fail to respond to DES with IVIG+rituximab. IL6/IL-6R signaling is critical for B-cell differentiation to plasmablasts and IgG production. Tocilizumab…
American Transplant Congress abstracts